What is Juniper Genomics?
Juniper Genomics is dedicated to transforming IVF care through its pioneering embryo screening test, which leverages both whole genome and transcriptome sequencing. Founded by distinguished experts in genomics, reproductive medicine, and bioethics, the company provides unparalleled comprehensive and clinically actionable insights. This advanced approach empowers patients and clinicians to make more informed decisions throughout the IVF process. Distinct from conventional methods, Juniper's technology analyzes millions of genetic markers associated with IVF failure, miscarriage, and post-birth health, notably avoiding the use of contentious polygenic risk scores. By integrating cutting-edge scientific advancements with a robust ethical framework, Juniper Genomics is actively shaping the future of reproductive technology and establishing a new standard for assessing embryo health.
How much funding has Juniper Genomics raised?
Juniper Genomics has raised a total of $4.6M across 1 funding round:
Seed
$4.6M
Seed (2025): $4.6M with participation from Blue Collective, Amboy Street Ventures, MBX Capital, and Innospark Ventures
Key Investors in Juniper Genomics
Blue Collective
Blue Collective is a venture capital and private equity firm that invests in exceptional individuals who are building remarkable businesses. They focus on a people-first and values-driven approach, employing a multi-strategy investment model.
Amboy Street Ventures
Amboy Street Ventures is the world's first venture capital fund focused on women's health and sexual wellbeing for all genders. The company invests in Seed and Series A stages of innovative startups that address critical areas such as fertility, menopause, maternal health, LGBTQ+ health, and sexual health.
MBX Capital
MBX Capital is a boutique venture capital firm that partners with and creates healthcare and biotechnology companies that are disrupting conventions in service to public health. MBX focuses primarily on early-stage companies that are inventing in overlooked domains of knowledge.
What's next for Juniper Genomics?
The substantial enterprise-level funding secured by Juniper Genomics signals a strong validation of its innovative approach to IVF care and embryo screening. This capital injection is expected to fuel significant expansion, likely focusing on scaling its proprietary sequencing technology, broadening clinical adoption, and further research and development into reproductive health solutions. The company's strategic focus on comprehensive genetic insights, coupled with its ethical underpinnings, positions it for leadership in the rapidly evolving fertility technology market. Future growth may also involve strategic partnerships within the broader healthcare and biotechnology sectors, potentially leveraging AI for enhanced diagnostic capabilities and patient outcomes.
See full Juniper Genomics company page
